The proxy consolidates Oramed's control post-acquisition, with a fully Oramed-aligned board and management. The massive potential dilution from the June 2026 notes/warrants (up to ~73% of current shares) is the key risk — watch for shareholder vote outcome on Proposal 5. The shift to all-equity director compensation signals cash constraints. Monitor for further management departures and any Oramed-related related-party transactions.
Price Chart
Executive Summary
Lifeward's 2026 proxy statement reveals a company in transition following the Oratech Acquisition and Oramed's emergence as a 44.2% controlling shareholder. The board has been reshuffled with Oramed affiliates, the CEO and CFO have departed, and shareholders are asked to approve massive potential dilution (up to ~73% of current shares) from convertible notes and warrants. The filing also seeks approval for a new all-equity director compensation plan to conserve cash, renewal of the compensation policy, and a say-on-pay vote. The activist SC 13D filed by Oramed in May 2026 preceded this control change, making this proxy a consolidation of Oramed's influence rather than a contested event.
Key Facts
- Oramed holds 44.2% of outstanding shares and is the controlling shareholder; three Oramed affiliates (Miriam Kidron, Yehuda Reznick, Avi Gabay) serve on the board, and the interim CEO Josh Hexter also serves as COO of Oramed.
- Shareholders are asked to approve issuance of shares beyond the 19.99% exchange cap under Nasdaq Rule 5635(d) — full conversion of the $5.58M notes and warrants could add ~2.07M shares, representing ~73% dilution of current 2.83M shares outstanding.
- CEO Mark Grant departed Aug 31, 2026; CFO Almog Adar steps down Sept 30, 2026; the company has had three CEOs in 2025-2026.
- 2025 net loss was $19.9M, worsening from $28.9M in 2024 and $22.1M in 2023; revenue and net income targets for 2025 bonuses were not achieved.
- Total 2025 CEO compensation: Mark Grant $834,866 (7 months), Larry Jasinski $798,201 (6 months + severance); CFO Almog Adar $472,375.
- Director compensation is proposed to shift to all-equity (annual RSUs worth $72,570 per director, $145,140 for chair) to conserve cash.
- Last year's say-on-pay vote passed with 1,129,220 FOR vs 658,819 AGAINST — a 63% approval rate, indicating notable shareholder dissent.
- The board has 8 seats but only 6 occupied; two external directors are required under Israeli law but only one currently serves.
Financial Impact
Potential dilution of up to ~73% from convertible notes and warrants; 2025 net loss of $19.9M; no revenue or net income targets achieved for bonuses.
Risk Factors
- Massive dilution risk: up to ~73% of current shares from convertible notes and warrants if fully converted/exercised.
- Controlling shareholder (Oramed) influence may lead to related-party transactions not aligned with minority holders.
- Cash burn continues with $19.9M net loss in 2025; all-equity director comp suggests cash conservation is critical.
- Management instability: three CEOs in 18 months, CFO departing, and key executives resigning.
- Say-on-pay approval was only 63% in 2025, indicating significant shareholder discontent with compensation practices.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001178913-26-004614 |
| Document: 0001178913-26-004614-index-headers.html | 0001178913-26-004614 |
| Document: 0001178913-26-004614-index.html | 0001178913-26-004614 |
| Document: 0001178913-26-004614.txt | 0001178913-26-004614 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 8-K | $6.49 $6.00 | ▲ +7.55% | ▲ +5.58% | $5.81 (+10.48%) |
Oct 1, 2026 26d ago | 8-K | $5.96 $6.43 | ▲ +7.89% | ▲ +6.58% | $5.81 (−2.52%) |
Sep 25, 2026 4w ago | DEF 14A | $6.92 $6.67 | ▲ +3.61% | ▲ +4.82% | $5.81 (+16.04%) |
Aug 14, 2026 10w ago | 8-K | $7.45 $7.32 | ▼ −1.75% | ▼ −0.38% | $5.81 (−22.01%) |
Aug 14, 2026 10w ago | Press Release | $7.45 $7.32 | ▲ +1.75% | ▲ +0.38% | $5.81 (+22.01%) |
Aug 11, 2026 11w ago | EFFECT | $7.57 $7.41 | ▲ +2.08% | ▲ +1.67% | $5.81 (+23.20%) |
Aug 7, 2026 11w ago | Press Release | $7.69 $7.45 | ▼ −3.06% | ▼ −3.46% | $5.81 (−24.40%) |
May 19, 2026 23w ago | 8-K | $6.40 $7.12 | ▲ +11.17% | ▲ +8.93% | $5.81 (−9.22%) |
May 15, 2026 23w ago | 8-K | $6.70 $7.05 | ▼ −5.22% | ▼ −4.26% | $5.81 (+13.28%) |
May 15, 2026 23w ago | Press Release | $6.70 $7.05 | ▼ −5.22% | ▼ −4.26% | $5.81 (+13.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers